EF Hutton Maintains Buy on Hoth Therapeutics, Raises Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
EF Hutton analyst Tim Moore maintains a Buy rating on Hoth Therapeutics (NASDAQ:HOTH) and raises the price target from $6.5 to $7.
April 02, 2024 | 1:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
EF Hutton analyst Tim Moore maintains a Buy rating on Hoth Therapeutics and raises the price target from $6.5 to $7.
The upgrade in the price target by a reputable analyst like Tim Moore from EF Hutton signals a positive outlook on Hoth Therapeutics' stock, potentially leading to increased investor confidence and a short-term price increase.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100